B
Bull
Bull · 25%MIST
$2.13
Precio del escenario
$1.140
-0.020 (-1.72%)Al cierre
Loading chart…
- High
- 1.155
- Open
- 1.140
- VWAP
- 1.14
- Vol
- 1.02M
- Mkt Cap
- 68.71M
- Low
- 1.115
- Amount
- 1.16M
- EV/EBITDA, TTM
- -0.11
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
AI analysis of Milestone Pharmaceuticals Inc (MIST)
buyMilestone Pharmaceuticals Inc is a good buy right now due to its recent positive developments, including a pivotal Phase 3 trial initiation for etripamil, which could significantly enhance its market position. The stock is currently priced at $1.16, and analysts have set a price target of $3, indicating a potential upside of over 150%. Additionally, the company reported a significant increase in prescriptions for its product, with Q2 2026 revenue reaching $559,000, a notable improvement from previous quarters. However, the main risk is the ongoing net losses, with a reported loss of $28.6 million in Q2 2026, which could impact future performance if not addressed.
Métricas de valoración
The current forward P/E ratio for Milestone Pharmaceuticals Inc (MIST) is 0.00, compared to its 5-year average forward P/E of -2.76.
Alphio AI Price Scenarios for MIST
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
9.008-21NASDAQ.COMMilestone Pharmaceuticals Initiates Pivotal Phase 3 Trial for Etripamil in AFib-RVR
2.008-21NewsfilterMilestone Initiates Phase 3 ReVeRA-301 Trial for Etripamil in AFib-RVR
9.508-19NASDAQ.COMMilestone Pharmaceuticals Reports Strong Q2 Results with Significant Growth in CARDAMYST Prescriptions
9.508-12NASDAQ.COMMilestone Pharmaceuticals Q2 Financial Results and Updates
- 5.007-03Newsfilter
Milestone Pharmaceuticals Grants 288,000 Options to Induce New Hires
MIST FAQ — answered by Alphio AI
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Milestone Pharmaceuticals Inc is a good buy right now due to its recent positive developments, including a pivotal Phase 3 trial initiation for etripamil, which could significantly enhance its market position. The stock is currently priced at $1.16, and analysts have set a price target of $3, indicating a potential upside of over 150%. Additionally, the company reported a significant increase in prescriptions for its product, with Q2 2026 revenue reaching $559,000, a notable improvement from previous quarters. However, the main risk is the ongoing net losses, with a reported loss of $28.6 million in Q2 2026, which could impact future performance if not addressed.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.